

Abstract

Over the last few decades, genetic engineering has become a powerful tool to alter, restore, or boost shape or function. Established in the late 20th century, recombinant DNA technologies have revolutionized the way we think about genetic modification. In the late 20th century, recombinant DNA technologies were used to create transgenic organisms, which have been used in a variety of ways, including crop improvement, medicine, and industry. More recently, the development of CRISPR/Cas systems has revolutionized genetic engineering, allowing for precise and targeted editing of the genome. This new technology has opened up a wide range of possibilities for genetic modification, including the creation of synthetic life forms. These synthetic life forms, typically referred to as synthetic biology, have supplemented these conventional methods [1].

CRISPR/Cas systems have revolutionized genetic engineering, allowing for precise and targeted editing of the genome. This new technology has opened up a wide range of possibilities for genetic modification, including the creation of synthetic life forms. These synthetic life forms, typically referred to as synthetic biology, have supplemented these conventional methods [1].

CRISPR/Cas systems have revolutionized genetic engineering, allowing for precise and targeted editing of the genome. This new technology has opened up a wide range of possibilities for genetic modification, including the creation of synthetic life forms. These synthetic life forms, typically referred to as synthetic biology, have supplemented these conventional methods [1].

B



References

1. Robert JS, Baylis F (2008) "Genetic engineering." *Int. Encycl Public Heal* 35-39.
2. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, et al. (2012) A

***Corresponding author:** Georgios Kargas, Department of Digital Systems, University of Piraeus, Piraeus 18534, Greece

Received: 01-Sep-2022, Manuscript No: jpgb-22-130, **Editor assigned:** 05-Sep-2022, Pre QC No: jpgb-22-130(PQ), **Reviewed:** 19-Sep-2022, QC No: jpgb-22-130, **Revised:** 26-Sep-2022, Manuscript No: jpgb-22-130 (R), **Published:** 30-Sep-2022, DOI: 10.4172/jpgb.1000130

Citation: Kargas G, Krithara A, Nentidis A, Palliouras G, Filippakis M (2022) Computational Methods for Improving Genetic Therapies for Duchene Muscular Dystrophy. *J Plant Genet Breed* 6: 130.

Copyright: © 2022 Kargas G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.